HARVARD BIOSCIENCE INC (HBIO) Stock Fundamental Analysis
USA - NASDAQ:HBIO - US4169061052 - Common Stock
0.6596 USD
+0.08 (+13.29%)
0.6501 USD
-0.01 (-1.44%)
Overall HBIO gets a fundamental rating of 3 out of 10. We evaluated HBIO against 58 industry peers in the Life Sciences Tools & Services industry. HBIO has a bad profitability rating. Also its financial health evaluation is rather negative. HBIO is cheap, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
HBIO had positive earnings in the past year.
HBIO had a positive operating cash flow in the past year.
In the past 5 years HBIO always reported negative net income.
In the past 5 years HBIO always reported a positive cash flow from operatings.
1.2 Ratios
HBIO has a worse Return On Assets (-71.67%) than 89.66% of its industry peers.
HBIO's Return On Equity of -364.88% is on the low side compared to the rest of the industry. HBIO is outperformed by 87.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.67% | ||
| ROE | -364.88% | ||
| ROIC | N/A |
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HBIO has a better Gross Margin (56.89%) than 74.14% of its industry peers.
HBIO's Gross Margin has been stable in the last couple of years.
HBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.89% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
2. Health
2.1 Basic Checks
HBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HBIO has more shares outstanding
HBIO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, HBIO has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -2.65, we must say that HBIO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of HBIO (-2.65) is worse than 79.31% of its industry peers.
There is no outstanding debt for HBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 8.44 | ||
| Altman-Z | -2.65 |
ROIC/WACCN/A
WACC10.86%
2.3 Liquidity
HBIO has a Current Ratio of 0.81. This is a bad value and indicates that HBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of HBIO (0.81) is worse than 91.38% of its industry peers.
A Quick Ratio of 0.41 indicates that HBIO may have some problems paying its short term obligations.
The Quick ratio of HBIO (0.41) is worse than 96.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.41 |
3. Growth
3.1 Past
HBIO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
HBIO shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -19.73% yearly.
Looking at the last year, HBIO shows a very negative growth in Revenue. The Revenue has decreased by -16.14% in the last year.
The Revenue has been decreasing by -4.12% on average over the past years.
EPS 1Y (TTM)0%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%100%
Revenue 1Y (TTM)-16.14%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-6.28%
3.2 Future
Based on estimates for the next years, HBIO will show a very strong growth in Earnings Per Share. The EPS will grow by 45.77% on average per year.
Based on estimates for the next years, HBIO will show a decrease in Revenue. The Revenue will decrease by -1.21% on average per year.
EPS Next Y-57.5%
EPS Next 2Y45.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.8%
Revenue Next 2Y-1.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
HBIO is valuated correctly with a Price/Earnings ratio of 16.49.
HBIO's Price/Earnings ratio is rather cheap when compared to the industry. HBIO is cheaper than 94.83% of the companies in the same industry.
HBIO is valuated rather cheaply when we compare the Price/Earnings ratio to 25.89, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 5.17, which indicates a rather cheap valuation of HBIO.
Based on the Price/Forward Earnings ratio, HBIO is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of HBIO to the average of the S&P500 Index (34.59), we can say HBIO is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.49 | ||
| Fwd PE | 5.17 |
4.2 Price Multiples
HBIO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HBIO is cheaper than 82.76% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HBIO indicates a rather cheap valuation: HBIO is cheaper than 100.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.11 | ||
| EV/EBITDA | 17.99 |
4.3 Compensation for Growth
HBIO's earnings are expected to grow with 45.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.77%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for HBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.6596
+0.08 (+13.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners58.21%
Inst Owner Change3.41%
Ins Owners3.72%
Ins Owner Change11.11%
Market Cap29.37M
Revenue(TTM)94.14M
Net Income(TTM)-57.41M
Analysts80
Price Target2.04 (209.28%)
Short Float %1.46%
Short Ratio0.76
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)38.73%
Min EPS beat(2)1.96%
Max EPS beat(2)75.49%
EPS beat(4)3
Avg EPS beat(4)-19.61%
Min EPS beat(4)-173.52%
Max EPS beat(4)75.49%
EPS beat(8)3
Avg EPS beat(8)-36.43%
EPS beat(12)5
Avg EPS beat(12)-34.08%
EPS beat(16)5
Avg EPS beat(16)-29.83%
Revenue beat(2)1
Avg Revenue beat(2)4.73%
Min Revenue beat(2)-1.72%
Max Revenue beat(2)11.18%
Revenue beat(4)1
Avg Revenue beat(4)-1.43%
Min Revenue beat(4)-14.86%
Max Revenue beat(4)11.18%
Revenue beat(8)1
Avg Revenue beat(8)-5.4%
Revenue beat(12)2
Avg Revenue beat(12)-5.25%
Revenue beat(16)3
Avg Revenue beat(16)-4.28%
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-50%
EPS NY rev (1m)0%
EPS NY rev (3m)-50%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.49 | ||
| Fwd PE | 5.17 | ||
| P/S | 0.33 | ||
| P/FCF | 7.11 | ||
| P/OCF | 4.43 | ||
| P/B | 1.87 | ||
| P/tB | N/A | ||
| EV/EBITDA | 17.99 |
EPS(TTM)0.04
EY6.06%
EPS(NY)0.13
Fwd EY19.33%
FCF(TTM)0.09
FCFY14.06%
OCF(TTM)0.15
OCFY22.55%
SpS1.99
BVpS0.35
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.56
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.67% | ||
| ROE | -364.88% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.89% | ||
| FCFM | 4.65% |
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
F-Score4
Asset Turnover1.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 8.44 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 36.42% | ||
| Cap/Sales | 2.81% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 223.33% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.41 | ||
| Altman-Z | -2.65 |
F-Score4
WACC10.86%
ROIC/WACCN/A
Cap/Depr(3y)33.21%
Cap/Depr(5y)26.48%
Cap/Sales(3y)2.31%
Cap/Sales(5y)1.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%100%
EPS Next Y-57.5%
EPS Next 2Y45.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-16.14%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-6.28%
Revenue Next Year-8.8%
Revenue Next 2Y-1.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4466.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.77%
OCF growth 3Y4.55%
OCF growth 5Y-29.12%
HARVARD BIOSCIENCE INC / HBIO FAQ
What is the ChartMill fundamental rating of HARVARD BIOSCIENCE INC (HBIO) stock?
ChartMill assigns a fundamental rating of 3 / 10 to HBIO.
What is the valuation status of HARVARD BIOSCIENCE INC (HBIO) stock?
ChartMill assigns a valuation rating of 7 / 10 to HARVARD BIOSCIENCE INC (HBIO). This can be considered as Undervalued.
Can you provide the profitability details for HARVARD BIOSCIENCE INC?
HARVARD BIOSCIENCE INC (HBIO) has a profitability rating of 2 / 10.
What is the expected EPS growth for HARVARD BIOSCIENCE INC (HBIO) stock?
The Earnings per Share (EPS) of HARVARD BIOSCIENCE INC (HBIO) is expected to decline by -57.5% in the next year.